Connect with us
PharmaMar's shares surged 32.7% after announcing positive phase III trial results for Zepzelca, combined with Tecentriq, in treating advanced small cell lung cancer. This combination significantly...
PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...
Grifols and PharmaMar significantly dropped Spanish pharmaceutical stocks, with declines of 49.1% and 22.5% respectively in the first half of 2024. Although other companies like Rovi...
PharmaMar's profits rebound with a 64% increase to 2.3 million euros in Q1 2024 compared to the same period last year. Total revenues dropped by 19.45%...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...
PharmaMar is a biopharmaceutical company based in Madrid, specializing in the discovery, development, and commercialization of new antitumor drugs of marine origin. The company has a...
PharmaMar wanted to highlight the growth in royalty income, which has increased by 8% compared to the same period of the previous year, reaching a total...
The company has confirmed that, as a result of its commitment to R&D in oncology, it has achieved a success rate of 37% in its research, compared...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...